The craze for junk-rated debt of some of the world’s riskiest countries has sent an emerging-market risk premium to the ...
Discovery stage biotechs are facing >,20% discount rates, clinical stage companies a lower discount rate and marketing stage companies an 8% market risk premium – the average market risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results